Having in mind that phosphoproteomics data has already been produced in the context of AKT activity and melanoma resistance to MAPK inhibitors (vemurafenib and selumetinib), one can envision that a similar approach could be used to detect a core regulatory network behind the interplay between AKT and MAPK cascades in melanoma kinase inhibitor resistance [73]. Here, AKT1 is linked to melanoma.